SOPHiA GENETICS S.A.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SOPHiA GENETICS S.A. (Nasdaq: SOPH) provides a cloud-native, AI-powered platform for data-driven medicine that analyzes complex multimodal healthcare data, including genomic, imaging, and clinical information, to deliver actionable insights for cancer, rare and hereditary disorders, infectious diseases, and other conditions; core offerings encompass the SOPHiA DDM Platform with specialized applications such as MSK-ACCESS and MSK-IMPACT for liquid biopsy and solid tumor analysis, SOPHiA DDM Dx solutions for hereditary cancer, RNA target oncology, homologous recombination deficiency, myeloid, and solid tumor diagnostics (CE-IVD marked in Europe, UK, Switzerland, and Israel), biomarker discovery services, radiomics for medical imaging, and the recently launched SOPHiA DDM Digital Twins for simulating patient treatment responses in research. The company serves over 1,000 healthcare institutions, clinical laboratories, biopharma firms, and research organizations across more than 70 countries, with key geographic operations in the US, Europe (including Switzerland, France, Italy, Spain, Belgium), Asia-Pacific (notably Japan), Latin America, Middle East, and Africa. Founded in 2011 and headquartered in Rolle, Switzerland, SOPHiA GENETICS operates as a publicly traded entity following its 2021 Nasdaq IPO, employing approximately 423-450 staff globally. Recent developments include strategic partnerships with Precision for Medicine to integrate SOPHiA DDM for biopharma biomarker discovery and clinical trials, Complete Genomics and Element Biosciences to co-market MSK assays on advanced sequencing platforms, A.D.A.M. Innovations for liquid biopsy testing in Japan, AstraZeneca expansions for breast/prostate cancer NGS detection of PIK3CA/AKT1/PTEN mutations via a Privileged Access Program, and Jessa Ziekenhuis in Belgium for oncology genomics; the company reported Q3 2025 revenue of $19.5 million (up 23% YoY), raised full-year 2025 guidance to $75-77 million with 15-18% growth, achieved 99,000 analyses (up 9% YoY) and 31 new customers, and surpassed 2 million cumulative genomic profiles analyzed.
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS Q2 Earnings Call Highlights
SOPHiA GENETICS Reports Second Quarter 2026 Results
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS Reports First Quarter 2026 Results
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026